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To investigate long-term treatment response after intravitreal bevacizumab injections
(IVBIs) for central serous chorioretinopathy (CSC).
Methods
This retrospective, interventional study investigated the medical records of 45 eyes of 44
patients with CSC who underwent IBVIs and completed at least 2-year follow-up period.
Complete resolution (CR) was defined as complete resolution of subretinal fluid at least 3
months after the last IVBI. Thick-choroid CSC was defined as mean subfoveal choroidal
thickness more than 300.0 μm. The main outcome measure was long-term treatment out-
come after IVBIs in patients with CSC.
Results
Thirty-five patients (79.5%) were male, and their mean age was 45.5 ± 9.6 years. The mean
follow-up period was 35.1 ± 11.5 months. Twenty-two eyes (48.9%) had acute CSC, and 40
eyes (88.9%) achieved CR. Twenty eyes (50.0%) developed recurrence, the mean number of
IVBIs to achieve the first CR was not significantly different between eyes with and without
recurrences (2.6 ± 1.6 vs. 2.9 ± 1.9; P = 0.658). Thick-choroid CSC was significantly difference
between the eyes with and without recurrence (17 eyes, 85.0% vs. eyes, 50.0%; P = 0.020).
Among the baseline characteristics, serous pigment epithelial detachment (B = - 2.580, P =
0.032) and thick-choroid (B = 1.980, P = 0.019) were significantly associated with recurrence.
Conclusion
Eyes with CSC treated with IVBI and achieving complete resolution of subretinal fluid have
50% chance of recurrence in the long term. Thinner choroid and serous pigment epithelial
detachment appear protective for recurrences.
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Introduction
Central serous chorioretinopathy (CSC) is characterized by serous neurosensory retinal
detachment at the posterior pole due to leakage from the retinal pigment epithelium (RPE) [1–
5]. Serous neurosensory macular detachment in patients with CSC leads to visual symptoms
involving metamorphopsia, blurred vision, and micropsia in a relatively young and middle-
aged population [1–5]. The majority of cases of acute CSC resolve spontaneously within 3
months [6–8]; however, early intervention for acute CSC has been advocated to prevent irre-
versible visual loss [9, 10]. About 10% of patients with acute CSC have multiple recurrences or
progression to a chronic course [4, 11]. Persistent serous retinal detachment in a patient with
chronic CSC can lead to permanent visual impairment due to RPE decompensation and dis-
ruption of the photoreceptor ellipsoid zone [1, 2, 12, 13]. Treatment modalities for CSC
include focal laser photocoagulation, photodynamic therapy (PDT), and intravitreal anti-vas-
cular endothelial growth factor (VEGF) injections [14].
Although some have evaluated the treatment efficacy of intravitreal anti-VEGF injections
for CSC [15–23], clinical outcome of anti-VEGF therapy for CSC have been inconsistent.
Some studies have indicated that intravitreal bevacizumab injections (IVBIs) may be helpful
for rapid resolution of sensory retinal detachment resulting in visual recovery, as 42–82.5% of
a study population showed complete resolution of subretinal fluid (SRF) [15–23]. However,
other studies have not shown a beneficial effect of IVBIs in patients with CSC [24–28]. One
study found no significant difference at the 6- and 12-month follow-up visit between IVBIs
and observation [26]. Other studies demonstrated a superior visual outcome in patients sub-
jected to observation compared to those who received IVBIs [27, 28]. Other anti-VEGF agents,
such as ranibizumab and aflibercept, have also been used for chronic CSC and seem to be
more effective for treatment-naïve or non-responsive cases than IVBIs with a short follow-up
period [29–31]. In addition, a few randomized studies have shown no superior efficacy of anti-
VEGF injections for CSC [28, 32].
In contrast to the mixed, varied clinical efficacy of intravitreal anti-VEGF injections, PDT
shows superior and consistent treatment outcomes [33–35]. Thus, PDT is considered a good
treatment option for patients with CSC. However, PDT requires specialized equipment, such
as a PDT laser machine, and possible complications include chorioretinal atrophy, secondary
choroidal neovascularization, and choroidal hypoperfusion [36–39]. Thus, intravitreal anti-
VEGF agents cannot be excluded as a treatment option for patients with CSC.
Although several studies have investigated the clinical efficacy of intravitreal anti-VEGF
agents for patients with CSC, no study has investigated the long-term treatment outcomes of
these patients. In this study, we investigated the long-term treatment outcome of IVBIs for
patients with CSC. In addition, we investigated the rates of recurrence and predictive factors
for recurrence in these patients.
Methods
Enrollment of study subjects
This retrospective interventional study was performed at the Catholic Kwandong University
College of Medicine, International St. Mary’s Hospital. We retrospectively reviewed the medi-
cal records of patients with macular-involved CSC who underwent IVBIs and completed at
least a 2-year follow-up. An IVBI was performed at 4-week intervals until complete resolution
of SRF. Then, IVBIs were performed on an as-needed basis as determined using spectral
domain optical coherence tomography (SD OCT) findings, such as the reappearance of SRF.
The exclusion criteria were: 1) other concomitant eye diseases, such as age-related macular
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degeneration, polypoidal choroidal vasculopathy, diabetic retinopathy, pathological myopia,
or retinal vein occlusion, which might affect choroidal thickness; 2) no prior history of PDT;
3) the presence of systemic diseases that require long-term systemic steroid treatment; and 4)
any intraocular surgery within 3 months. This study was approved by the Institutional Review
Board of International St. Mary’s Hospital, Catholic Kwandong University College of Medi-
cine, and adhered to the tenets of the Declaration of Helsinki. Because of the retrospective
nature of this study, the Institutional Review Board waived the need for informed consent.
CSC is defined by choroidal congestion and choroidal hyperpermeability, which leads to
focal RPE defects and the formation of serous pigment epithelium detachment. Chronic CSC
is defined as a symptom duration and/or persistent serous retinal detachment of more than 3
months. Recurrence of CSC is defined as the reappearance of SRF after at least a 3-month
period with complete resolution of a previous CSC. Complete resolution of CSC is defined as
complete resolution of serous macular detachment or resolution of SRF by at least 3 months
after the last IVBI.
We also classified the study population into two groups according to the baseline subfoveal
choroidal thickness (SFCT) measured by SD OCT: Thick-choroid CSC was defined as a mean
SFCT of more than 300.0 μm at the time of the initial diagnosis and during the follow-up period.
The primary outcome measure was the treatment response to IVBIs during a follow-up
period of at least 2 years. The secondary outcome was the appearance following IVBIs of possi-
ble factors correlated with the recurrence of CSC.
Ocular examination
An ophthalmologic examination, including a slit-lamp examination, an intraocular pressure
measurement using a non-contact tonometer, and a fundus examination after pupillary dila-
tion were performed at each visit. The refractive error of each eye was measured using an auto-
refractor and converted to spherical equivalents [diopters (D)]. Fundus autofluorescence
images and SD OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany) were taken
with an enhanced depth imaging modality. Both fluorescein angiography and indocyanine
green angiography were performed using the Heidelberg Retina Angiograph system (HRA-2;
Heidelberg Engineering) with a confocal scanning laser ophthalmoscope for diagnosis of CSC
at the first visit. At each follow-up visit, the best-corrected visual acuity (BCVA) of the affected
eye(s) with CSC was checked with a decimal visual acuity chart, and then each value was con-
verted to a logarithm of the minimum angle of resolution (logMAR).
Evaluation by spectral domain optical coherence tomography
Serial cross-sectional horizontal scans of approximately 121 μm apart in a 30 × 30˚ macular
area were obtained for the macular evaluation. Single horizontal and vertical scans across the
fovea were also obtained separately.
At least two good-quality horizontal and vertical scans across the fovea were obtained for each
eye to measure the SFCT. The choroidal thickness was defined as the perpendicular distance
from the outer border of the hyper-reflective line, corresponding to the RPE, to the chorio-scleral
interface. Using digital calipers provided by the Heidelberg Spectralis OCT software, the choroi-
dal thickness was measured horizontally and vertically at the subfoveal region in each trans-sec-
tional image, and the average measurement was calculated. Two independent observers (HMK
and JHC), who were blinded to the clinical data, measured the choroidal thickness.
The central macular thickness (CMT) was defined as the mean retinal thickness in the cen-
tral subfield, a region with a diameter of 1.0 mm around the fovea. The inner and the outer
rings had diameters of 3.0 mm and 6.0 mm, respectively. The CMT in the 9-standard early
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treatment diabetic retinopathy study (ETDRS) macular grid subfields was automatically calcu-
lated by the Heidelberg software. All SD OCT images were reviewed for any possibility of seg-
mentation errors, and the ETDRS grid was manually centered at the fovea.
The height of the SRF, presence of flat irregular pigment epithelial detachment (PED), pres-
ence of serous PED, presence of hyper-reflective speckles in the SRF, and presence of RPE
humps were evaluated in each eye. The height of the SRF was manually measured at the high-
est point between the photoreceptor ellipsoid zone and the RPE. The presence of choroidal
hyperpermeability was evaluated by ICGA. Choroidal hyperpermeability was defined as focal
areas of hyper-fluorescence with blurred margins on mid- and late-phase images. Classic CSC
was defined as focal or multifocal detachment of the neurosensory retina on fluorescein angi-
ography (FA), or an RPE with single or multifocal areas of leakage at the late phase.
Statistical analysis
The data are presented as mean ± standard deviation (range). Baseline characteristics included
age, sex, refractive error, BCVA, and chronicity of CSC at the time of the initial visit. The mean
SFCT, the greatest height of the SRF, and various imaging characteristics, such as choroidal
hyperpermeability, flat irregular PED, and serous PED, were also evaluated. IBM SPSS Statistics
software for Windows, version 22.0 (IBM Corp., Somers, NY, USA) was used for statistical analy-
ses. The Kruskal–Wallis test was used for continuous variables, and the chi-square test was used
for categorical variables when the clinical characteristics were compared between eyes with and
without recurrence. Repeated-measured analysis of variance was used to compare the mean
BCVA, the mean SFCT, and the mean CMT during the follow-up period. To investigate the pos-
sible predictive factors for the recurrence of CSC after the IVBIs, binary regression analysis using
the forward analysis method was used. Mauchly’s test of sphericity and Kolmogorov–Smirnov
analyses were used to confirm statistical validity. A P-value< 0.05 was considered significant.
Results
Baseline characteristics of the study population
A total of 45 eyes from 44 patients with CSC were included in this study. The mean age at the
time of diagnosis was 45.5 ± 9.6 years (20–59 years), and the mean follow-up duration was
35.1 ± 11.5 months (24–68 months). Twenty-two eyes (48.9%) had acute CSC, and 40 eyes
(88.9%) achieved complete resolution. The mean BCVA was 0.2 ± 0.2 (0–0.6) logMAR at baseline,
and 0.1 ± 0.1 (0–0.4) logMAR at 24 months (P< 0.001) after a mean of 4.4 ± 3.4 (1–17) IVBIs in
overall population. None of the study population showed choroidal neovascularization (CNV).
In 40 eyes with at least one complete resolution, the mean number of IVBIs to the first com-
plete remission was 2.7 ± 1.7 injections (1–7 injections). The mean BCVA was 0.2 ± 0.2 (0–
0.6) logMAR at baseline, and 0.1 ± 0.2 (-0.1–0.6) logMAR at final visit (P = 0.018). The mean
CMT was 387.6 ± 105.0 (198.0–661.0) μm at baseline, and 252.2 ± 47.1 (178.0–410.0) at final
visit (P < 0.001). The mean SFCT was 402.7 ± 127.5 (243.0–646.0) μm at baseline, and
377.5 ± 129.7 (247.0 to 641.5) μm at final visit (P< 0.001).
Five patients (11.1%) did not achieve complete resolution of CSC after the IVBIs, and were
referred for PDT. The detailed clinical characteristics of these five patients are shown in Table 1.
Recurrence after intravitreal bevacizumab injections for central serous
chorioretinopathy
Among 40 eyes showing at least one complete resolution, 20 eyes (50.0%) developed at least one
recurrence (mean 1.5 ± 0.8 recurrences; 1–2 times). The mean number of IVBIs for the first
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resolution was 2.9 ± 1.9 times (1–7 times) in eyes without recurrence and 2.6 ± 1.6 times (1–6
times) in those with recurrence (P = 0.658). However, the total number of IVBIs was signifi-
cantly different between eyes with and without recurrence (mean 5.2 ± 3.1 vs. 2.9 ± 1.9 times,
respectively; P = 0.010). The mean duration between the first complete resolution to the first
recurrence was 11.6 ± 6.4 months (4–43 months). The mean BCVA at baseline was 0.2 ± 0.2 (0–
0.6) logMAR in the eyes with recurrence, and 0.2 ± 0.2 (-0.1–0.4) logMAR in the eyes without
recurrence (P = 0.620). The mean BCVA at the final visit was 0.1 ± 0.2 (0–0.6) logMAR in the
eyes with recurrence, and 0.1 ± 0.2 (-0.1–0.4) in the eyes without recurrence (P = 0.495).
The mean height of the SRF at baseline was 189.7 ± 111.0 μm (29.0–487.0 μm) in eyes without
recurrence, and 150.8 ± 101.3 μm (32.0–378.0 μm) in eyes with recurrence (P = 0.224). The mean
CMT was not significantly different between eyes with and without recurrence at baseline
(379.5 ± 109.0 vs. 406.9 ± 100.5 μm, respectively; P = 0.165) and at the final visit (264.9 ± 54.7 vs.
238.8 ± 34.1 μm, respectively; P = 0.194). The mean SFCT was significantly thicker in eyes with
recurrence than in those without recurrence at baseline (441.9 ± 96.9 vs. 366.8 ± 144.1 μm, respec-
tively; P = 0.043) and the final visit (416.2 ± 108.5 vs. 332.7 ± 139.0 μm, respectively; P = 0.028).
Comparison of baseline characteristics between eyes with and without
recurrence of central serous chorioretinopathy after intravitreal
bevacizumab injections
After assessing the recurrence rate and comparing the clinical outcomes between the eyes with
and without recurrence, we compared the baseline characteristics in the eyes with and without
recurrence after IVBIs for CSC.
No significant differences in baseline clinical characteristics were observed, including the
mean age at the time of diagnosis, sex, total follow-up period, and mean symptom duration
Table 1. Characteristics of the five patients who did not have at least one complete resolution of central serous chorioretinopathy after the intravitreal bevacizumab
injections.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (years) 53 39 41 42 60
Sex Male Female Female Male Male
Chronicity Acute Acute Chronic, recurrent Chronic, recurrent Chronic recurrent
Previous treatment Observation Observation Focal laser
Refractive errors (diopters) 0 –0.25 –0.25 –3.75 1.25
Total number of IVBIs 10 11 11 12 10
BCVA at the time of diagnosis (logMAR) 0.3 0.2 0.2 0.3 0.2
BCVA at last visit (logMAR) 0.3 0.1 0.2 0.1 0.3
SRF height at the time of diagnosis (μm) 94.0 58.0 35.0 221.0 351.0
SRF height at the last visit (μm) 35.0 48.0 38.0 53.0 73.0
CMT at the time of diagnosis (μm) 256 380 301 443 384
Serous PED - - - - -
Flat irregular PED + - - + +
Choroidal hyperpermeability on ICGA + - - + +
Hyper-reflective speckles in SRF - - - + +
Mean SFCT at the time of diagnosis (μm) 565.0 93.0 481.0 469.0 269.0
Mean SFCT at last visit (μm) 525.0 71.0 422.0 417.0 238.5
Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness; ICGA, indocyanine green angiography; IVBI, intravitreal bevacizumab injection;
logMAR, logarithm of the minimum angle of resolution; PED, pigment epithelial detachment; SFCT, subfoveal choroidal thickness; SRF, subretinal fluid.
https://doi.org/10.1371/journal.pone.0238725.t001
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(P = 0.212, P = 0.531, P = 0.870, and P = 0.273, respectively). Twelve eyes (60.0%) with acute
CSC did not develop a recurrence, and six eyes (30.0%) with acute CSC developed a recurrence
(P = 0.055).
We also compared the ocular imaging characteristics between the eyes with and without
recurrence in these patients. Serous PED was present in six (30.0%) of the eyes without recur-
rence, and in one (5.0%) of the eyes with a recurrence (P = 0.046). We also classified the eyes
into relatively thin-choroid CSC (mean SFCT < 300.0 μm) and thick-choroid CSC (mean
SFCT� 300.0 μm), and the presence of thick-choroid CSC was higher in eyes with recurrence
than in those without: 13 eyes (85.0%) vs. 10 eyes (50.0%), respectively (P = 0.020). A detailed
comparison of the baseline characteristics of eyes with and without a recurrence is shown in
Table 2.
Factors associated with recurrence after the intravitreal bevacizumab
injections for central serous chorioretinopathy
We investigated the baseline factors that were significantly associated with recurrence after
IVBIs for CSC. Among the various baseline characteristics, the presence of serous PED (B =
-2.580, P = 0.032) and thick-choroid CSC (B = 1.980, P = 0.019) were significantly associated
with recurrence after IVBIs in these patients (Table 3).
Representative figures are shown in Figs 1–3.
Discussion
In this study, we evaluated the long-term treatment response to IVBIs in patients with CSC,
and investigated the baseline characteristics predictive of recurrence in this study population.
During a follow-up period of at least 2 years, 88.9% of the patients with CSC developed at least
one complete resolutionwith a mean of 2.7 IVBIs. During the mean follow-up period of 35
months, half of the eyes with at least one complete resolution showed at least one recurrence.
The final BCVA was not significantly different between eyes with and without recurrence,
Table 2. Comparison of baseline characteristics between eyes with and without recurrence after complete remission with intravitreal bevacizumab injections
(IVBIs) for central serous chorioretinopathy.
Eyes without recurrence (20 eyes) Eyes with recurrence (20 eyes) P-value
Mean age at the time of diagnosis (years) 47.2 ± 10.1 43.3 ± 9.1 0.212�
Mean refractive error (diopters) −0.7±1.6 −0.4 ± 1.2 0.562�
Mean symptom duration (months) 2.3 ± 3.1 5.5 ± 11.5 0.273�
Mean number of IVBIs to the first remission 2.9 ± 1.9 2.6 ± 1.6 0.658�
Mean total number of IVBIs 2.9 ± 1.9 5.2 ± 3.1 0.010�
Acute CSC (%) 12 (60.0%) 6 (30.0%) 0.055†
Hyper-reflective speckles in the SRF (%) 9 (45.0%) 6 (30.0%) 0.257†
Choroidal hyperpermeability on ICGA (%) 5 (30.0%) 9 (45.0%) 0.160†
Flat irregular PED (%) 3 (15.0%) 6 (30.0%) 0.225†
Serous PED (%) 6 (30.0%) 1 (5.0%) 0.046†
RPE humps (%) 13 (65.0%) 8 (40.0%) 0.102†
Thick choroid (%) 10 (50.0%) 17 (85.0%) 0.020†
Abbreviations: CSC, central serous chorioretinopathy; ICGA, indocyanine green angiography; PED, pigment epithelial detachment; RPE, retinal pigment epithelium;
SRF, subretinal fluid.
�The Mann–Whitney U-test for continuous variables, and the †chi-square test for categorical variables were used for the statistical analysis. A P-value < 0.05 was
considered significant.
https://doi.org/10.1371/journal.pone.0238725.t002
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Table 3. Possible baseline predictive factors for recurrence after intravitreal bevacizumab injections for patients
with central serous chorioretinopathy during a long-term follow-up period by binary logistic regression analysis.
Factors β P-value
Chronicity 1.029 0.310
BCVA at baseline 0.315 0.574
Height of SRF at baseline 0.152 0.697
CMT at baseline 0.064 0.800
Hyper-fluorescent speckles in SRF 3.496 0.062
Choroidal hyperpermeability on ICGA 0.002 0.969
Mixed autofluorescence in FAF images 0.427 0.513
Flat irregular PED 0.093 0.760
Serous PED -2.580 0.019
RPE humps 1.448 0.229
Classic FA patterns 2.051 0.152
Mean SFCT at baseline 1.560 0.212
Thick choroid 1.980 0.019
Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness; FA, fluorescein angiography;
ICGA, indocyanine green angiography; logMAR, logarithm of the minimum angle of resolution; PED, pigment
epithelial detachment; RPE, retinal pigment epithelium; SFCT, subfoveal choroidal thickness; SRF, subretinal fluid.
https://doi.org/10.1371/journal.pone.0238725.t003
Fig 1. Image from 37-year-old male patient with central serous chorioretinopathy (CSC) in both eyes. The patient had a history of CSC 11 years prior that resolved
spontaneously. He also had a recent recurrence of CSC in both eyes for 4 months and was referred to our hospital due to persistent subretinal fluid (SRF) in the right
eye. The best-corrected visual acuity (BCVA) was 0.1 logarithm of the minimum angle of resolution (logMAR) in the right eye. (A) Subretinal fluid (SRF) at fovea with
photoreceptor ellipsoid zone blurring was noted. Hyper-reflective dots in SRF was also noted. (B) A single intravitreal bevacizumab injection (IVBI) led to complete
resolution of SRF, but small retinal pigment epithelial detachment (PED) was noted. (C) After 11 months, CSC recurred showing profuse subretinal fluid, and two more
IVBIs were performed to resolve the SRF (D). (E) SRF also developed in the left eye, and the BCVA was 0.1 logMAR at the time of recurrence. After the first IVBI, SRF
resolved completely (F), however, SRF recurred after 1 month (G). (H) Two more IVBIs were needed in the left eye to resolve the SRF, and (I) CSC recurred after 18
months. (J) Two IVBIs were needed to resolve the SRF of the recurred CSC.
https://doi.org/10.1371/journal.pone.0238725.g001
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Fig 2. Image from a 49-year-old male patient with central serous chorioretinopathy (CSC) in the right eye. The subretinal fluid (SRF) in the right eye did not resolve
after 3 months, and the patient was referred to our hospital. At the time of diagnosis, the best-corrected visual acuity (BCVA) was 0.2 logarithm of the minimum angle of
resolution (logMAR) in the right eye. (A) Subretinal fluid (SRF) with retinal pigment epithelium humps and focal photoreceptor ellipsoid zone disruption was noted.
Intravitreal bevacizumab injection (IVBI) was performed, but SRF was aggravated (B). Second IVBI also did not improve SRF (C), however, 3rd IVBI much improved
SRF (D). Subsequent 4th (E), 5th (F), 6th (G) IVBI did not completely resolve SRF, but 7th IVBI led to complete resolution of SRF, and CSC did not recur for 15 months
after last IVBI. The BCVA was 0.3 logMAR at the last visit.
https://doi.org/10.1371/journal.pone.0238725.g002
Fig 3. Image from a 34-year-old female patient with acute central serous chorioretinopathy (CSC) in the right eye. She complained of blurred vision in the right eye
for 2 months, and the best-corrected visual acuity (BCVA) was 0.3 logarithm of the minimum angle of resolution (logMAR). (A) Subretinal fluid (SRF) with hyper-
reflective dots was noted. (B) A single intravitreal bevacizumab injection (IVBI) led to resolution of SRF, and the BCVA improved to 0 logMAR. (C) After 24 months,
CSC recurred, and the BCVA in the right eye was 0.5 logMAR. (D) IVBI was performed, but SRF did not completely resolve, and (E) additional IVBI was needed to
resolve the SRF, and the BCVA improved to 0.2 logMAR.
https://doi.org/10.1371/journal.pone.0238725.g003
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although the eyes without recurrence showed better visual outcomes. The mean SFCTs at base-
line and the final visit were significantly thicker in eyes with a recurrence than in those with-
out. Among the various baseline factors, the presence of serous PED and the thin-choroid type
of CSC was negatively correlated with recurrence of CSC.
The long-term treatment results of this study suggest that IVBIs can remain as a treatment
option for patients with CSC. Previously, some studies have investigated the cytokines in the
aqueous humor of patients with CSC, resulting in inconsistent results [40–43]. Some studies
suggest that aqueous VEGF level was not significantly elevated in the patients with CSC, sup-
porting ineffectiveness of anti-VEGF therapy in these patients [40, 41]. However, other studies
have shown different findings. One study demonstrated that the VEGF-A level is significantly
higher in bevacizumab responders than in non-responders, suggesting that VEGF may con-
tribute to the pathogenesis of CSC [42]. Another study found that proinflammatory cytokines,
such as interleukin (IL)-6 and IL-8, are significantly upregulated in patients with chronic CSC
compared to those with acute CSC [43]. Angiogenic cytokines and VEGF-A are also upregu-
lated more in patients with CSC than in those with acute CSC [43]. IVBIs significantly reduce
choriocapillaris endothelial cell fenestrations [44, 45]. In addition, SFCT, choroidal vascular
hyperpermeability, and choroidal blood flow decrease significantly after IVBIs in patients with
CSC [17, 22, 46–49]. Along with these previous studies, majority of our study population
showed at least one complete resolution, with a maximum of seven IVBIs. Repeated IVBI treat-
ments in some patients in our study also led to a final complete resolution of CSC.
In addition to the clinical efficacy of IVBIs, the possible predictive factors for patients being
good responders to IVBIs have been investigated in patients with CSC. These predictive fac-
tors, such as hyperfluorescence on ICGA, classic FA findings, and a relatively thick SFCT, have
been reported in multiple studies [16, 17, 46, 47]. Some studies have shown that presence of
CNV can be more responsive for anti-VEGF therapy [50, 51], none of our study population
showed CNV. In contrast to the previously known factors for good responders, we found that
the presence of serous PED and thin-choroid CSC were significantly associated with a low pos-
sibility of recurrence. however, Our study demonstrated favorable results of the IVBIs, which
is inconsistent with previous studies, suggesting that a thicker SFCT is predictive of patients
being good responders to IVBIs [17, 46, 47]. However, the majority of our study population
was considered to be good responders to IVBIs: nearly 90% of the patients showed at least one
complete resolution after the IVBIs. Thus, among these CSC patients who responded well to
the IVBIs, relativelythinner baseline SFCT may reflect a weaker disease activity, resulting in
less recurrence during the long-term follow-up period.
Our study is the first attempt to investigate the presence of relatively thin-choroid CSC and
its clinical significance to IVBIs. The results of this study show that relatively thin-choroid
CSC occurred among the study population, and the presence of thick-choroid CSC seemed to
be associated with higher possibility of recurrence after IVBIs. Because the mean SFCT appears
to reflect disease activity, such as choroidal hyperpermeability in patients with CSC [52], rela-
tively thin-choroid CSC may indicate lower disease activity in these patients. Relatively thin
choroid in eyes with CSC may indicate lower hydrostatic pressure. Although the exact patho-
physiology of CSC is still under investigation, RPE decompensation and choroidal hyperper-
meability seem to be involved [2, 53, 54]. Increased choroidal extravasated fluid from the
hyperpermeable choroidal vessels induces an elevation of hydrostatic pressure in the choroid.
This elevated hydrostatic pressure exerts mechanical stress on the RPE layer, leading to RPE
detachment by fluid that is forced anteriorly through Bruch’s membrane. If rupture or perme-
ability of the RPE increases, it leads to leakage into the subretinal space, resulting in serous reti-
nal detachment [2, 53, 54]. Thus, thickening of the choroid in a patient with CSC may reflect
more hydrostatic pressure associated with choroidal hyperpermeability, suggesting higher
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disease activity. Then, it can be speculated that patients with relatively thin-choroid CSC have
less disease activity than those with thick-choroid CSC at the time of disease development,
leading to a good treatment response and less of a possibility of recurrence after IVBIs in these
patients. However, this cannot fully explain the treatment response of CSC to the IVBIs,
because two of five eyes that did not show complete resolution had relatively thin-choroid
CSC. Thus, relatively thin-choroid CSC cannot entirely explain the treatment response to
IVBIs, and further studies are needed to clarify the clinical significance of relatively thin-cho-
roid CSC. In addition, the treatment response of relatively thin-choroid CSC and thick-cho-
roid CSC to PDT and/or intravitreal anti-VEGF injections should be further investigated.
In addition to relatively thin-choroid CSC, the presence of serous PED was negatively asso-
ciated with a recurrence of CSC in our study. During the pathogenesis of CSC, serous PED can
occur due to hydrostatic pressure associated with choroidal hyperpermeability [2, 53, 54]. In
our study, acute CSC tended to be more prevalent in eyes without recurrence than in those
with recurrence, but it did not reach statistical significance. However, serous PED tended to be
more prevalent in acute CSC (N = 5, 27.8%) than chronic CSC (N = 2, 9.1%; P = 0.130). Serous
PED in CSC has been observed to spontaneously regress in more than 60% of cases over a
long-term follow-up period [55], and serous PED in chronic CSC may become vascularized
PED [56].Thus, the presence of serous PED may indirectly reflect the chronicity of CSC. We
speculate that more acute CSC may recur less long-term after IVBIs by reducing choroidal
hyperpermeability in the early stage of the disease. This result also indirectly supports previous
results that emphasized the importance of early intervention for CSC [9, 10].
Another interesting point is that the mean BCVA was not significantly different in eyes
with and without recurrence in our study population. In the overall study population, IVBIs
led to significant visual improvement during the follow-up period. The BCVA in each patient
did not decrease much during the follow-up period, even in patients without complete resolu-
tion. Thus, the visual deterioration associated with CSC may not be rapid regardless of the
treatment response or recurrence during continuous IVBI treatment. However, our patients
underwent repeated treatment with IVBIs, and vision changes cannot be the deciding point
for treatment. Persistent serous retinal detachment and the resulting disruption of the photo-
receptor ellipsoid zone can lead to permanent visual deterioration in the patients with CSC.
Thus, timely intensive treatment for CSC is needed to prevent permanent visual loss despite
vision changes, and the decision to change the treatment regimen is important in these
patients.
However, we cannot conclude that anti-VEGF therapy is superior to PDT, combination
therapy of PDT with anti-VEGF agents, or observation because our study lacks the control
groups. This study was not comparative, and about 10% of the study population did not show
complete resolution despite repeated IVBIs. We terminated the IVBIs and referred the latter
patients to other hospitals at which PDT was available. In addition, it is possible that early
intervention with PDT might have shortened the treatment period in some of our patients
who underwent repeated IVBIs. It is also possible that some patients with acute or chronic
CSC might spontaneously resolve regardless of IVBIs. Thus, we cannot propose that IVBIs can
replace PDT, combination therapy of PDT with anti-VEGF agents, or observation when treat-
ing the patients with CSC. Our study results suggest that IVBIs still can remain as a treatment
option for CSC, as the treatment showed some efficacy during a long-term follow-up period.
Our results suggest that IVBIs can be considered as a treatment option, even over the long-
term period in the clinical settings in which PDT is not available, or for the patients who are
concerned about PDT-induced complications [34–37], but request early intervention than
simple observation.
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This study had several limitations, including a relatively small study population and a retro-
spective design. Because our hospital lacks the capability to deliver PDT, we could not compare
the treatment efficacies of PDT and IVBIs, which may limit the application of our findings.
We also lack the control group of simple observation, because most of the our patients
requested early intervention than observation. Abscence of the control group limit comparison
of treatment efficacy among the treatment strategies in the patients with CSC. In addition, our
study population was a mixture of patients with acute and chronic CSC. A further prospective
study that compares IVBIs to PDT, combination therapy of PDT with IVBIs, and observation
will be needed to elucidate the treatment efficacy in patients with CSC. In addition, interven-
tion for acute and chronic CSC is also recommended.
In conclusion, about 90% of eyes with CSC showed at least one complete remission during
a mean follow-up period of 35 months. The presence of serous PED and thin-choroid CSC at
the time of diagnosis was significantly associated with a low possibility of recurrence in
patients with CSC.
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